The combination of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) with vascular endothelial growth factor (VEGF) blockade has been shown to produce an improved progression-free survival in patients with advanced lung cancer [3,4,5]. This evidence concerns the gene EGFR and lung cancer.